TITLE

A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries

AUTHOR(S)
Waning, Brenda; Diedrichsen, Ellen; Moon, Suerie
PUB. DATE
January 2010
SOURCE
Journal of the International AIDS Society;2010, Vol. 13 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Indian manufacturers of generic antiretroviral (ARV) medicines facilitated the rapid scale up of HIV/ AIDS treatment in developing countries though provision of low-priced, quality-assured medicines. The legal framework in India that facilitated such production, however, is changing with implementation of the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights, and intellectual property measures being discussed in regional and bilateral free trade agreement negotiations. Reliable quantitative estimates of the Indian role in generic global ARV supply are needed to understand potential impacts of such measures on HIV/AIDS treatment in developing countries. Methods: We utilized transactional data containing 17,646 donor-funded purchases of ARV tablets made by 115 low- and middle-income countries from 2003 to 2008 to measure market share, purchase trends and prices of Indian-produced generic ARVs compared with those of non-Indian generic and brand ARVs. Results: Indian generic manufacturers dominate the ARV market, accounting for more than 80% of annual purchase volumes. Among paediatric ARV and adult nucleoside and non-nucleoside reverse transcriptase inhibitor markets, Indian-produced generics accounted for 91% and 89% of 2008 global purchase volumes, respectively. From 2003 to 2008, the number of Indian generic manufactures supplying ARVs increased from four to 10 while the number of Indian-manufactured generic products increased from 14 to 53. Ninety-six of 100 countries purchased Indian generic ARVs in 2008, including high HIV-burden sub-Saharan African countries. Indian-produced generic ARVs used in first-line regimens were consistently and considerably less expensive than non-Indian generic and innovator ARVs. Key ARVs newly recommended by the World Health Organization are three to four times more expensive than older regimens. Conclusions: Indian generic producers supply the majority of ARVs in developing countries. Future scale up using newly recommended ARVs will likely be hampered until Indian generic producers can provide the dramatic price reductions and improved formulations observed in the past. Rather than agreeing to inappropriate intellectual property obligations through free trade agreements, India and its trade partners - plus international organizations, donors, civil society and pharmaceutical manufacturers - should ensure that there is sufficient policy space for Indian pharmaceutical manufacturers to continue their central role in supplying developing countries with lowpriced, quality-assured generic medicines.
ACCESSION #
64933584

 

Related Articles

  • Point: Subsidizing AIDS Drugs in the U.S. and Abroad. Anderson, Tim // Points of View: Subsidizing HIV/AIDS Drugs;3/1/2016, p5 

    This article presents an argument on subsidizing AIDS drugs in the United States and abroad. The worldwide AIDS epidemic has taken an enormous toll on life in both the industrialized and developing world. AIDS is spreading throughout Eastern Europe, Asia and Africa. As of 2003, it was the...

  • Subsidizing HIV/AIDS Drugs: An Overview. Farrell, Courtney; English, Marlanda // Points of View: Subsidizing HIV/AIDS Drugs;3/1/2016, p1 

    The article examines the debate over the provision of subsidies for antiretroviral drug treatment by the U.S. government. The prices of antiretroviral drugs are lower in developing countries than in the U.S. and Western Europe. Moreover, generic versions of such drugs may be produced in...

  • Which Patients First? Setting Priorities for Antiretroviral Therapy Where Resources Are Limited. McGough, Laura J.; Reynolds, Steven J.; Quinn, Thomas C.; Zenilman, Jonathan M. // American Journal of Public Health;Jul2005, Vol. 95 Issue 7, p1173 

    The availability of limited funds from international agencies for the purchase of antiretroviral (ARV) treatment in developing countries presents challenges, especially in prioritizing who should receive therapy. Public input and the protection of human rights are crucial in making treatment...

  • Point: The AIDS Emergency in Africa. Clouthier, Kris // Points of View: AIDS Drugs in Africa;3/29/2019, p5 

    This article presents an argument in favor of providing AIDS drugs to African nations. The magnitude of the global AIDS pandemic is reaching alarming heights in the developing world. Of the 42 million people who have the HIV virus in 2003, over 29 million of them live in Africa, and 99 percent...

  • Out of step on AIDS.  // New Scientist;6/29/91, Vol. 130 Issue 1775, p13 

    Focuses on the inequalities between industrialized and developing countries in managing AIDS. Inability of developing to gain access to antiviral drug zidovudine; Claim that HIV infection is difficult to transmit and relatively stoppable; Failure of biotechnology companies to provide low-cost...

  • WHO insists it can meet its target for antiretrovirals by 2005. Fleck, Fiona // BMJ: British Medical Journal (International Edition);7/17/2004, Vol. 329 Issue 7458, p129 

    Announces that the World Health Organization is undertaking a huge international effort to get lifesaving antiretroviral treatment to AIDS sufferers in poor countries by the end of 2005. Statistics of WHO's assistance to AIDS victims; Enthusiastic response to the campaign; Price of...

  • Is the "3 by 5" Initiative the Best Approach to Tackling the HIV Pandemic? Jim Yong Kim; Ammann, Arthur // PLoS Medicine;Nov2004, Vol. 1 Issue 2, p97 

    Presents opposing views on the 3 by 5 Initiative of the World Health Organization to treat people infected with HIV in poor and middle income countries by the end of 2005. Background on the use of antiretroviral therapy in the project; Principles about the HIV pandemic; Factors influencing the...

  • Recent Publications, Information and Events.  // WHO Drug Information;2006, Vol. 20 Issue 3, p200 

    This article focuses on the health publications, information, and events worldwide. The publications are presented including "Untangling the Web of Price Reductions: a Pricing Guide for the Purchase of ARVs for Developing Countries" by Medicins Sans Frontieres (MSF) in October 2001, "From Access...

  • Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Boerma, J. Ties; Stanecki, Karen A.; Newell, Marie-Louise; Chewe Luo; Beusenberg, Michel; Garnett, Geoff P.; Little, Kirsty; Garcia Calleja, Jesus; Crowley, Siobhan; Jim Yong Kim; Zaniewski, Elizabeth; Walker, Neff; Stover, John; Ghys, Peter D. // Bulletin of the World Health Organization;Feb2006, Vol. 84 Issue 2, p145 

    This paper reviews the data sources and methods used to estimate the number of people on, and coverage of, antiretroviral therapy (ART) programmes in low- and middle-income countries and to monitor the progress towards the "3 by 5" target set by WHO and UNAIDS. We include a review of the data...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics